Publisher Correction: Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation.

Weng, Jui-Hsia; Koch, Peter David; Luan, Harding H; Tu, Ho-Chou; Shimada, Kenichi; Ngan, Iris; Ventura, Richard; Jiang, Ruomu; Mitchison, Timothy J.

Weng JH; Department of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. jui-hsia_weng@hms.harvard.edu.
Koch PD; Department of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Luan HH; Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA.
Tu HC; NGM Biopharmaceuticals, South San Francisco, CA, USA.
Shimada K; Alnylam Pharmaceuticals, Inc., Cambridge, MA, USA.
Ngan I; Department of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Ventura R; NGM Biopharmaceuticals, South San Francisco, CA, USA.
Jiang R; NGM Biopharmaceuticals, South San Francisco, CA, USA.
Mitchison TJ; Department of Systems Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.

Nat Metab ; 3(5): 728, 2021 May.

Article en En | MEDLINE | ID: mdl-33953392

ABSTRACT

A Correction to this paper has been published https//doi.org/10.1038/s42255-021-00397-5.

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2021 Tipo del documento: Article